As of May 30, 2026, Agios Pharmaceuticals's top three insider holders are Brian Goff (Chief Executive Officer, 184.51K shares), Jacqualyn A Fouse (Chief Executive Officer, 151.34K shares), David P Schenkein (Chief Executive Officer, 126.24K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| John Maraganore | - | 30,028 | 0 | 24 May, 2022 |
| Jeffrey D Capello | - | 6,073 | 0 | 23 Jun, 2025 |
| Kaye I Foster-Cheek | - | 7,468 | 0 | 23 Jun, 2025 |
| Ian T Clark | - | 6,549 | 0 | 24 May, 2022 |
| Jacqualyn A Fouse | Chief Executive Officer | 151,340 | 0 | 23 Jun, 2025 |
| Paul J Clancy | - | 6,549 | 0 | 24 May, 2022 |
| Brian Goff | Chief Executive Officer | 184,508 | 0 | 06 Apr, 2026 |
| David P Schenkein | Chief Executive Officer | 126,242 | 0 | 17 Jun, 2024 |
| Cynthia Smith | - | 12,414 | 0 | 13 Aug, 2025 |
| Maykin Ho | - | 17,032 | 0 | 23 Jun, 2025 |
| David Scadden | - | 17,603 | 0 | 14 Nov, 2025 |
| Jonathan Biller | Chief Financial Officer | 22,953 | 0 | 23 Feb, 2022 |
| Bruce Car | Chief Scientific Officer | 16,752 | 0 | 23 Feb, 2022 |
| Adams Catherine Owen | - | 6,073 | 0 | 23 Jun, 2025 |
| Cecilia Jones | Chief Financial Officer | 54,998 | 0 | 06 Apr, 2026 |
| Theodore James Jr. Washburn | Principal Accounting Officer | 868 | 0 | 05 Mar, 2026 |
| Sarah Gheuens | Chief Medical Officer | 80,277 | 0 | 06 Apr, 2026 |
| Richa Poddar | Chief Commercial Officer | 8,508 | 0 | 18 Oct, 2022 |
| James William Burns | Chief Legal Officer | 49,306 | 0 | 06 Apr, 2026 |
| Tsveta Milanova | Chief Commercial Officer | 46,829 | 0 | 06 Apr, 2026 |
| Krishnan Viswanadhan | Chief Corp Dev Strategy | 10,282 | 0 | 06 Apr, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Apr, 2026 | Brian Goff | Common stock | A | 25,528 | $0.00 | 190,076 | D | M |
| 02 Apr, 2026 | Sarah Gheuens | Common stock | A | 8,500 | $0.00 | 83,217 | D | M |
| 02 Apr, 2026 | Krishnan Viswanadhan | Common stock | A | 8,100 | $0.00 | 13,241 | D | M |
| 02 Apr, 2026 | James William Burns | Common stock | A | 8,500 | $0.00 | 52,586 | D | M |
| 02 Apr, 2026 | Krishnan Viswanadhan | Common stock | A | 8,100 | $0.00 | 13,241 | D | M |
| 02 Apr, 2026 | Cecilia Jones | Common stock | A | 8,500 | $0.00 | 58,139 | D | M |
| 02 Apr, 2026 | Tsveta Milanova | Common stock | A | 8,500 | $0.00 | 50,091 | D | M |
| 02 Apr, 2026 | Sarah Gheuens | Common stock | D | 2,940 | $34.71 | 80,277 | D | S |
| 02 Apr, 2026 | Krishnan Viswanadhan | Common stock | D | 2,959 | $34.71 | 10,282 | D | S |
| 02 Apr, 2026 | James William Burns | Common stock | D | 3,280 | $34.71 | 49,306 | D | S |
| 02 Apr, 2026 | Krishnan Viswanadhan | Common stock | D | 2,959 | $34.71 | 10,282 | D | S |
| 02 Apr, 2026 | Tsveta Milanova | Common stock | D | 3,262 | $34.71 | 46,829 | D | S |
| 02 Apr, 2026 | Cecilia Jones | Common stock | D | 3,141 | $34.71 | 54,998 | D | S |
| 02 Apr, 2026 | Brian Goff | Common stock | D | 12,472 | $34.71 | 177,604 | D | S |
| 02 Apr, 2026 | James William Burns | Performance share units | D | 8,500 | $0.00 | 8,500 | D | M |
| 02 Apr, 2026 | Sarah Gheuens | Performance share units | D | 8,500 | $0.00 | 8,500 | D | M |
| 02 Apr, 2026 | Cecilia Jones | Performance share units | D | 8,500 | $0.00 | 8,500 | D | M |
| 02 Apr, 2026 | Tsveta Milanova | Performance share units | D | 8,500 | $0.00 | 8,500 | D | M |
| 02 Apr, 2026 | Krishnan Viswanadhan | Performance share units | D | 8,100 | $0.00 | 8,100 | D | M |
| 02 Apr, 2026 | Krishnan Viswanadhan | Performance share units | D | 8,100 | $0.00 | 8,100 | D | M |